Related Experiment Video
Updated: Aug 11, 2026
Multiplexed Fluorometric ImmunoAssay Testing Methodology and Troubleshooting
Published on: December 12, 2011
Automated immunofluorometric assay for MUC1
Insights
A new automated immunofluorometric assay (MUC1 IFMA) for the breast cancer marker MUC1 was developed and validated. This reliable assay shows comparable results to commercial tests and will aid in finding optimal MUC1 assays.
Area of Science:
- Biochemistry
- Immunology
- Oncology
Background:
- The MUC1 tumor-associated antigen is a significant biomarker in breast cancer diagnostics.
- Developing robust and automated assays is crucial for reliable MUC1 monitoring.
- Existing commercial assays for MUC1 present limitations in automation and evaluation capacity.
Purpose of the Study:
- To establish a robust, reliable, and fully automated immunofluorometric assay for the breast cancer serum marker MUC1 (MUC1 IFMA).
- To serve as a prototype for evaluating new MUC1 assays based on novel antibody combinations.
- To compare the performance of the new MUC1 IFMA with existing commercial assays.
Main Methods:
- Development of an automated immunofluorometric assay (MUC1 IFMA) utilizing time-resolved fluorescence.
- Comparison of MUC1 IFMA with two commercial assays: CA15-3 EIA (CanAg) and ETI-CA-15-3 K (Sorin).
- Evaluation of assay performance metrics including coefficient of variation and diagnostic sensitivity/specificity.
Main Results:
- The MUC1 IFMA demonstrated a coefficient of variation below 10% across a wide concentration range (9–2,400 kU/l).
- Overall diagnostic sensitivities were comparable across the three assays (MUC1 IFMA: 0.40, CA15-3 EIA: 0.37, ETI-CA-15-3 K: 0.38) at 0.94 specificity.
- All assays showed high sensitivity (close to 0.80) when applied to metastatic breast cancer samples, with a strong correlation (Spearman rank = 0.99) between MUC1 IFMA and CA15-3 EIA.
Conclusions:
- The automated MUC1 IFMA is a reliable and robust assay suitable for clinical application and research.
- The assay's performance is comparable to established commercial tests, offering improved automation and capacity.
- The MUC1 IFMA principle provides a valuable platform for the rapid evaluation of new antibody combinations for optimal MUC1 detection.
Abstract:
The aim of the present study was to establish a robust, reliable and fully automated immunofluorometric assay for the breast cancer serum marker MUC1. This would further serve as a prototype assay for evaluation of other MUC1 assays based on new antibody combinations. Using time-resolved fluorescence as tracer signal we developed an automated immunofluorometric assay for MUC1 (MUC1 IFMA). This assay was compared with two commercial assays. The CA15-3 EIA (CanAg) which use the same antibodies as the MUC1 IFMA, and the ETI-CA-15-3 K (Sorin) which use the original antibodies defining the CA 15-3 assay. The three assays showed comparable results. The coefficient of variation was below 10% from 9 to 2,400 kU/l for the MUC1 IFMA, from 15 to 250 kU/l for the CA15-3 EIA, and from 25 to 200 kU/l for the ETI-CA-15-3 K assay. At a specificity of 0.94 the overall diagnostic sensitivities for the MUC1-IFMA, CA15-3 EIA and ETI-CA-15-3 K assays were 0.40, 0.37, and 0.38, respectively. When applied to metastatic breast cancer, all assays had sensitivities close to 0.80. There was a close correlation (Spearman rank = 0.99) between results from the new assay and the CA15-3EIA. The new automated assay was not strictly immunometric as we could not achieve conditions where solid phase or tracer antibodies were in apparent excess. However, the assay performed well at a wide range of assay conditions. The automation, which minimizes imprecision in pipetting and handling of samples, and the high capacity of the AutoDELFIA instrument enabling measurement of all samples in a single run, were important aspects for establishing a reliable assay. The principle of the new automated immunofluorometric assay will be used as a rapid and reliable evaluation of a wide range of monoclonal antibody combinations in our search for the optimal MUC1 assay. This new automated immunofluorometric assay will be useful in the rapid and reliable evaluation of a wide range of monoclonal antibody combinations in our search for the optimal MUC1 assay.
